What Happened

The Therapeutic Goods Administration has concluded that the majority of AI medical scribes it examined likely qualify as medical devices under Australian law, a finding that could require vendors to register their products on the Australian Register of Therapeutic Goods before continuing to operate.
The TGA undertook the review after concerns arose that expanding feature sets were taking some products outside their original scope. The agency identified around 100 suppliers of digital scribes in Australia and sent them a voluntary survey, which received 40 responses. It then focused its detailed assessment on the 12 most widely used tools, from companies including Heidi, Lyrebird, Microsoft, Abby Health, VoiceBox, and iMedX.
Eight of those 12 products "included functions likely to meet the definition of a medical device," the TGA concluded. Two required "additional information to determine their regulatory status," and just two were considered "unlikely to be medical devices."
Why It Matters
The TGA's findings carry direct compliance implications for vendors selling into the Australian market. Products listed on the ARTG must meet design, validation, and safety standards before they can be lawfully supplied. Vendors found to be operating outside that framework face potential enforcement action.
The review also raises questions about clinical transparency. As the TGA noted, "When digital scribes make diagnostic or treatment recommendations, it may not always be clear how information has been selected, prioritised or generated," and "this makes it difficult for users to understand the basis of the output and assess its reliability."
Key Details
The TGA's concern centres on how AI scribes have evolved. "Many of these products were originally designed and marketed to support transcription, documentation and administrative tasks," the agency stated. Over time, however, many have added features that allow them to "analyse information and generate outputs that may influence clinical decisions."
Under Australian law, a medical device includes software intended to "diagnose, monitor, predict, provide a prognosis, treat, alleviate or compensate for a disease, injury or disability." The TGA's position is that where a scribe generates clinical recommendations or patient-specific outputs, it crosses that threshold.
"Where software generates clinical recommendations, conclusions or other patient-specific outputs that support clinical decision-making, those functions must be designed, validated and supported with appropriate safeguards," the agency stated in its published review.
Background and Context
AI scribe adoption among Australian GPs has grown sharply. According to Information Age, the proportion of GPs using the tools rose from 22 per cent in a 2024 survey to 40 per cent by the end of 2025. Vendors have signalled plans to expand capabilities further as the underlying AI models improve.
The TGA maintains the ARTG, which lists all therapeutic products approved for sale in Australia. The agency's review found that many scribe vendors "may not have previously considered" their obligations under that framework, partly because the products were initially positioned as administrative aids rather than clinical tools.
What Comes Next
The TGA has not announced enforcement timelines, but its published review signals that vendors whose products "included functions likely to meet the definition of a medical device" will need to engage with the regulator. Those requiring "additional information to determine their regulatory status" have been asked to provide it.
Vendors planning further capability expansions face the prospect of each new feature triggering a fresh regulatory assessment. The agency's review makes clear that the administrative-versus-clinical distinction will be scrutinised as AI scribes become more deeply embedded in consultation workflows.